PRCT · PROCEPT BioRobotics Corporation
$19.83
-0.65% last session
End-of-day data · close of 2026-10-26
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-17.0
Dividend yield
0.0%
Beta
0.92
Avg volume
1M
Employees
1K
Daily Change %
-0.65%
5 Days Change
14.00%
10 Days Change
4.87%
30 Days Change
10.72%
60 Days Change
-5.74%
Month to Day Change
17.69%
Year to Day Change
-36.33%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PRCT
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-07
Latest call per bank · past 12 months
Barclays
Overweight$30.00
+50.3% vs priceWells Fargo
Overweight$34.00
+70.3% vs priceBank of America
Underperform$20.00
+0.2% vs priceUBS
Buy$62.00
+210.6% vs priceMorgan Stanley
Overweight$51.00
+155.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Barclays | Initiates | Overweight | $0.00 → $30.00 |
| 2026-08-05 | TD Cowen | Maintains | Buy | $34.00 → $28.00 |
| 2026-08-05 | Piper Sandler | Maintains | Overweight | $35.00 → $25.00 |
| 2026-08-05 | Evercore ISI Group | Maintains | Outperform | $30.00 → $23.00 |
| 2026-08-05 | William Blair | Downgrade | Outperform → Market Perform | $0.00 |
| 2026-07-06 | Truist Securities | Downgrade | Buy → Hold | $30.00 → $25.00 |
| 2026-06-24 | Evercore ISI Group | Initiates | Outperform | $0.00 → $30.00 |
| 2026-06-11 | Leerink Partners | Downgrade | Outperform → Market Perform | $31.00 → $29.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 56 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 1.6% above the 50-day MA ($19.51).
- bearish: Price vs 200-day MA: Trading 15.8% below the 200-day MA ($23.56).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.30) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($16.69) and high ($36.95).
PRCT Price Chart
Loading chart for PRCT…
Fundamentals
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
More in Medical Devices
ABT
Abbott Laboratories
$179B -16.2% YTD
MDT
Medtronic plc.
$122B 3.1% YTD
SYK
Stryker Corporation
$118B -11.9% YTD
BSX
Boston Scientific Corporation
$66B -51.7% YTD
EW
Edwards Lifesciences Corporatio
$51B 5.7% YTD
GEHC
GE HealthCare Technologies Inc.
$33B -12.8% YTD
DXCM
DexCom, Inc.
$29B 18.0% YTD
PHG
Koninklijke Philips N.V. NY Reg
$26B 3.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.